Vicebio utilizes patented Molecular Clamp technology to stabilize viral glycoproteins in their pre-fusion conformation, enabling the development of fully liquid vaccines. The company focuses on creating effective vaccines to combat life-threatening respiratory viral infections, such as RSV and hMPV.
Funding
$118M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TCFounders
Product
Problem
Respiratory Syncytial Virus (RSV) and human Metapneumovirus (hMPV) pose significant threats, especially to infants and the elderly. Traditional vaccine development faces challenges in creating stable and broadly protective formulations against these viruses. Current vaccine approaches may not always elicit a robust or long-lasting immune response.
Solution
Vicebio is developing fully liquid vaccines for respiratory viral infections, including RSV and hMPV, using its patented Molecular Clamp technology. This technology stabilizes viral glycoproteins in their pre-fusion conformation, which is crucial for eliciting a strong and broadly protective immune response. The resulting vaccines are designed to be ready-to-use and easily manufactured. By focusing on the pre-fusion conformation, Vicebio aims to create more effective vaccines that offer enhanced protection against these life-threatening respiratory viruses.
Target Audience
The primary target audience includes infants, young children, and the elderly, who are particularly vulnerable to severe complications from RSV and hMPV infections.
Features
- Utilizes Molecular Clamp technology to stabilize viral glycoproteins.
- Focuses on the pre-fusion conformation of viral proteins for enhanced immunogenicity.
- Developing fully liquid vaccine formulations for ease of use.
- Targets life-threatening respiratory viral infections such as RSV and hMPV.
- Aims for broad protection against viral variants.
- Designed for seamless manufacturability and scalability.